Stakeholders across the healthcare system are demanding proactive disease management and objective measurement of treatment efficacy. Accurate physiological measurements made at the point of care are intended to give doctors the information they need to actively manage their patients. The Transdermal GFR Measurement system is intended to be a key measurement tool that may provide data on kidney function (GFR) which could be helpful to doctors both in their role in treating patients as well as in their research.*
Application of the MediBeacon technology in gastroenterology is focused on developing a transdermal measurement of gastrointestinal permeability. Increased gut permeability has been proposed to be an indicator of gut inflammation, a primary target in the treatment of Inflammatory Bowel Disease. Initial clinical studies to determine the utility of MediBeacon fluorescent tracer agents in monitoring and possibly aiding in diagnosis of Crohn’s patients have been completed.*
MediBeacon technology is built upon focused areas of innovation. Novel fluorescent tracer agents and highly engineered transdermal sensors along with unique analytical approaches are focused on delivering systems which have the potential to have a positive impact on the quality and cost of patient care. The MediBeacon intellectual property portfolio includes granted composition of matter, algorithm, and method patents in the US, Europe and beyond.
FDA granted the MediBeacon Transdermal GFR Measurement System (TGFR) Breakthrough Device designation in 2018. FDA Breakthrough Device Designation is reserved for technologies that have the potential to be more effective at diagnosing a life-threatening or irreversibly debilitating disease or condition compared to the current standard of care.
Grants from the Bill & Melinda Gates Foundation have supported MediBeacon transdermal gastroenterology permeability research.
Statements on this website may include forward-looking statements within the meaning of certain securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.